Auna's Q3 volume gains support margin recovery, but leverage remains key

What happened

Auna's preliminary Q3 results showed stronger hospital activity across Peru, Colombia, and Mexico, with surgeries up 11.7% year-over-year, while higher occupancy, oncology expansion, and contractual price adjustments are expected to support an EBITDA margin recovery in H2 2026. The stock trades at approximately 4.5x forward EV/EBITDA, below its historical average, which prompted a Strong Buy recommendation from Seeking Alpha. However, the company's net leverage remains elevated at 3.7x trailing net debt/EBITDA with interest coverage near 1.6x, making margin recovery essential for meaningful deleveraging. The news does not yet confirm sustained free cash flow or a reduction in leverage, which are the core checkpoints for the investment thesis. As a result, the positive volume data is encouraging but insufficient on its own to validate a rerating.

Implication

If EBITDA margin recovery and deleveraging materialize as suggested, the stock could re-rate toward the base case of $5.20, but risks remain around Mexico margin execution and covenant headroom.

Thesis delta

The thesis was already a potential buy with moderate conviction, contingent on sustained FCF and declining leverage. The news provides early evidence of volume recovery but does not yet confirm margin improvement or deleveraging. Therefore, no material shift in thesis; conviction remains conditional on Q3 data showing leverage below 3.7x and FCF near S/100M+ per quarter.